The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung ...

Raymond Osarogiagbon, MD, highlights the potential benefits of increasing screening rates for patients diagnosed with lung cancer and the broader US health care system.